A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 12 lat i waga co najmniej 45 kg
- •Białaczka ostra z określonymi zmianami genetycznymi (NPM1mt, KMT2Ar lub NUP98r)
- •Stan ogólny pozwalający na leczenie (stopień 2 lub lepszy w skali ECOG dla dorosłych)
- •Szpik kostny bez widocznych blastów (poniżej 5%) po chemioterapii, z drobnymi śladami choroby potwierdzonymi badaniem
- •Frakcja wyrzutowa serca większa niż 40%
- •Prawidłowa funkcja wątroby i nerek
- •Zdolność połykania tabletek
- •Zgoda pacjenta lub opiekuna na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- September 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Johns Hopkins University
Baltimore, United States
Dana-Farber Cancer Center
Boston, United States
Memorial Sloan Kettering Cancer Center
New York, United States
MD Anderson Cancer Center
Houston, United States
Trial contact
Ghayas Issa, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.